NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $71.46 +0.76 (+1.07%) Closing price 04:00 PM EasternExtended Trading$71.38 -0.08 (-0.12%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ANI Pharmaceuticals Stock (NASDAQ:ANIP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$70.07▼$71.4850-Day Range$70.23▼$86.0352-Week Range$69.96▼$99.39Volume228,889 shsAverage Volume330,101 shsMarket Capitalization$1.64 billionP/E Ratio15.40Dividend YieldN/APrice Target$105.57Consensus RatingModerate Buy Company Overview ANI Pharmaceuticals, Inc. is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging. ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners. Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 147th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingANI Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialANI Pharmaceuticals has a consensus price target of $105.57, representing about 47.7% upside from its current price of $71.46.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.83% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.83% in the coming year, from $7.83 to $8.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 15.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.73.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 15.40, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.81.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.94% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 9.22.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 1.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.67 News SentimentANI Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows3 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,728,385.00 in company stock.Percentage Held by Insiders8.10% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its BoardSeptember 4, 2026 | finance.yahoo.comANI Pharmaceuticals to Present at September Investor ConferencesSeptember 3, 2026 | globenewswire.comThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this supercycle - and says that may be conservative. Billionaire Pierre Lassonde has argued for $19,000. Former CIA advisor Jim Rickards targets $27,000 based on a federal revaluation of the gold supply. But the bigger opportunity may not be gold itself. A 'backdoor' gold-linked asset has historically multiplied gold's move by 10x or more - returning 846%, 1,668%, 1,847%, and 1,915% in the last supercycle.September 10 at 1:00 AM | Traders Agency (Ad)Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) StockSeptember 2, 2026 | insidertrades.com2 reasons to like ANIP (and 1 not so much)August 27, 2026 | msn.comANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 SharesAugust 27, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 500 Shares of StockAugust 14, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) SVP Ori Gutwerg Sells 3,162 SharesAugust 12, 2026 | insidertrades.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $78.94 at the start of the year. Since then, ANIP stock has decreased by 9.5% and is now trading at $71.46. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its earnings results on Friday, August, 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals's revenue was up 25.8% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? Top institutional shareholders of ANI Pharmaceuticals include California State Teachers Retirement System (8.64%), Ranger Investment Management L.P. (1.51%), Deutsche Bank AG (1.42%) and William Blair Investment Management LLC (1.13%). Insiders that own company stock include Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Thomas Haughey, Patrick D Walsh, Thomas Andrew Rowland, Renee P Tannenbaum, Jeanne Thoma, Antonio R Pera and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/07/2026Today9/10/2026Wells Fargo 21st Annual Healthcare Conference9/10/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ANIP's financial health is in the Red zone, according to TradeSmith. ANIP has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$105.57 High Price Target$121.00 Low Price Target$90.00 Potential Upside/Downside+47.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$4.64 Trailing P/E Ratio15.40 Forward P/E Ratio9.13 P/E GrowthN/ANet Income$78.34 million Net Margins11.07% Pretax Margin14.57% Return on Equity27.37% Return on Assets10.47% Debt Debt-to-Equity Ratio0.99 Current Ratio2.91 Quick Ratio2.41 Sales & Book Value Annual Sales$883.37 million Price / Sales1.86 Cash Flow$10.04 per share Price / Cash Flow7.12 Book Value$24.03 per share Price / Book2.97Miscellaneous Outstanding Shares22,970,000Free Float21,109,000Market Cap$1.64 billion OptionableOptionable Beta0.45 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ANIP) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBlackRock and Vanguard already own THISInstitutions own roughly 88 percent of an overlooked American oil and natural gas company. BlackRock holds 32 ...Monument Traders Alliance | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
